Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

Abstract

Abstract The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life‐threatening bleeding and mortality.

Keywords

• COVID‐19
• cytomegalovirus colitis
• double‐barrel colostomy
• lower gastrointestinal bleeding
• tocilizumab